{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.7621","value":"8.180"},{"groupId":"OG001","spread":"8.7302","value":"7.914"},{"groupId":"OG002","spread":"10.2846","value":"11.948"}]}],"title":"Bodily Pain Score: Wk 24 (n=115,106,85)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.4616","value":"9.815"},{"groupId":"OG001","spread":"9.3335","value":"9.323"},{"groupId":"OG002","spread":"10.3962","value":"12.712"}]}],"title":"Bodily Pain Score: Wk 48 (n=116,101,87)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.8122","value":"4.941"},{"groupId":"OG001","spread":"8.7345","value":"4.996"},{"groupId":"OG002","spread":"8.1955","value":"4.812"}]}],"title":"General Health Score: Wk 24 (n=112,108,85)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.9736","value":"6.470"},{"groupId":"OG001","spread":"8.9124","value":"6.340"},{"groupId":"OG002","spread":"8.4496","value":"6.241"}]}],"title":"General Health Score: Wk 48 (n=115,100,87)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.5160","value":"5.173"},{"groupId":"OG001","spread":"11.5165","value":"4.138"},{"groupId":"OG002","spread":"8.1965","value":"5.312"}]}],"title":"Mental Health Score: Wk 24 (n=115,107,85)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.6356","value":"6.607"},{"groupId":"OG001","spread":"12.3225","value":"4.979"},{"groupId":"OG002","spread":"11.0695","value":"4.939"}]}],"title":"Mental Health Score: Wk 48 (n=116,101,86)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.6418","value":"5.517"},{"groupId":"OG001","spread":"8.2243","value":"6.261"},{"groupId":"OG002","spread":"9.4105","value":"7.081"}]}],"title":"Physical Functioning Score: Wk 24 (n=111,108,85)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.6382","value":"6.529"},{"groupId":"OG001","spread":"9.8785","value":"6.318"},{"groupId":"OG002","spread":"10.9439","value":"8.577"}]}],"title":"Physical Functioning Score: Wk 48 (n=114,102,88)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.9256","value":"5.951"},{"groupId":"OG001","spread":"12.5182","value":"4.571"},{"groupId":"OG002","spread":"12.0934","value":"7.180"}]}],"title":"Emotional Role Score: Wk 24 (n=113,108,85)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.0187","value":"6.445"},{"groupId":"OG001","spread":"12.4357","value":"6.350"},{"groupId":"OG002","spread":"13.4771","value":"7.142"}]}],"title":"Emotional Role Score: Wk 48 (n=114,101,86)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.1079","value":"6.473"},{"groupId":"OG001","spread":"9.7472","value":"5.994"},{"groupId":"OG002","spread":"9.6101","value":"6.385"}]}],"title":"Physical Role Score: Wk 24 (n=113,108,84)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.0663","value":"7.347"},{"groupId":"OG001","spread":"9.8317","value":"7.493"},{"groupId":"OG002","spread":"9.6133","value":"7.873"}]}],"title":"Physical Role Score: Wk 48 (n=115,101,87)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.8861","value":"5.786"},{"groupId":"OG001","spread":"11.1663","value":"7.070"},{"groupId":"OG002","spread":"9.8518","value":"6.722"}]}],"title":"Social Functioning Score: Wk 24 (n=115,108,86"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.9376","value":"7.382"},{"groupId":"OG001","spread":"11.1880","value":"7.807"},{"groupId":"OG002","spread":"11.3046","value":"7.713"}]}],"title":"Social Functioning Score: Wk 48 (n=116,102,88)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.7057","value":"6.796"},{"groupId":"OG001","spread":"10.2488","value":"6.495"},{"groupId":"OG002","spread":"8.8644","value":"6.534"}]}],"title":"Vitality Score: Wk 24 (n=115,108,86)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.6821","value":"9.088"},{"groupId":"OG001","spread":"10.2350","value":"7.479"},{"groupId":"OG002","spread":"10.3652","value":"7.200"}]}],"title":"Vitality Score: Wk 48 (n=116,102,86)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"108"},{"groupId":"OG002","value":"88"}],"units":"Participants"}],"description":"SF-36 scores were obtained by scoring participants' responses to a 36 item questionnaire. SF-36 evaluated 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health from a range of 1 (better) to 5 (worst). The score for each section was an average of the individual question scores, which were scaled 0-100 (100=highest level of functioning). These 8 aspects were summarized as physical and mental component scores.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received rituximab, 0.5 g, IV, on Days 1, 15, 168, and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG000","title":"Rituximab Low Dose + Methotrexate"},{"description":"Participants received rituximab, 0.5 g, IV, on Days 1 and 15 and 1.0 g, IV, on Days 168 and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG001","title":"Rituximab Escalated Dose Methotrexate"},{"description":"Participants received rituximab, 1.0 g, IV, on Days 1, 15, 168, and 182. Participants also received methylprednisolone 100 mg, IV, by slow infusion, which was completed at least 30 minutes prior to each infusion of rituximab Days 1, 15, 168, and 182. Participants also received methotrexate 10-25 mg/mL, PO or parenterally, as prescribed by the treating physician and in accordance with the local label. Participants also received a stable dose of folate ≥ 5 mg/week given either as a single dose or as a divided weekly dose.","id":"OG002","title":"Rituximab High Dose + Methotrexate"}],"paramType":"MEAN","populationDescription":"ITT-M2 population, n = number of participants analyzed for the given parameter at the specified timepoint.","reportingStatus":"POSTED","timeFrame":"BL, Weeks 24 and 48","title":"Change in SF-36 Score From BL","type":"SECONDARY","unitOfMeasure":"score on a scale"}